| CTRI Number |
CTRI/2025/12/099338 [Registered on: 17/12/2025] Trial Registered Prospectively |
| Last Modified On: |
17/12/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Diagnostic |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
A Study to Assess a New Blood Test for Early Detection of Leptospirosis in Patients Attending a Tertiary Care Hospital in Kancheepuram District |
|
Scientific Title of Study
|
Clinical Evaluation of a Novel Multiplex PCR Panel (LipL21, LipL32, LipL41) for Leptospirosis Diagnosis in Kancheepuram District |
| Trial Acronym |
NILL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr.Farida Fahhima A |
| Designation |
Postgraduate |
| Affiliation |
Saveetha Medical College and Hospital |
| Address |
Department of Community Medicine , third floor, Saveetha medical college and hospital, Poonamallee , Chennai, Kuthambakkam, Tamil Nadu 602105 ,India . Saveetha medical college and hospital, Poonamallee,Chennai,Kuthambakkam, Tamil Nadu 602105, India . Chennai TAMIL NADU 602105 India
Kancheepuram TAMIL NADU 600040 India |
| Phone |
9345153967 |
| Fax |
|
| Email |
farida.7fahhima@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr.Nisha B |
| Designation |
Associate Professor |
| Affiliation |
Saveetha Medical College and Hospital |
| Address |
Department of Community Medicine , third floor, Saveetha medical college and hospital, Poonamallee , Chennai, Kuthambakkam, Tamil Nadu 602105 ,India .
Kancheepuram TAMIL NADU 600040 India |
| Phone |
9884713773 |
| Fax |
|
| Email |
Nishab.smc@saveetha.com |
|
Details of Contact Person Public Query
|
| Name |
Dr.Nisha B |
| Designation |
Associate Professor |
| Affiliation |
Saveetha Medical College and Hospital |
| Address |
Department of Community Medicine, third floor, Saveetha medical college and hospital, Poonamallee , Chennai, Kuthambakkam, Tamil Nadu 602105 ,India.
Kancheepuram TAMIL NADU 600040 India |
| Phone |
9884713773 |
| Fax |
|
| Email |
Nishab.smc@saveetha.com |
|
|
Source of Monetary or Material Support
|
|
|
Primary Sponsor
|
| Name |
Farida Fahhima A |
| Address |
Saveetha medical college and hospital, Poonamallee,Chennai,Kuthambakkam, Tamilnadu 602105 ,India . |
| Type of Sponsor |
Other [Self] |
|
|
Details of Secondary Sponsor
|
| Name |
Address |
| NOT APPLICABLE |
NOT APPLICABLE |
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Farida Fahhima A |
Saveetha Medical College and Hospital Institutional Ethics Committee |
Department of Community Medicine , third floor, Saveetha medical college and hospital, Poonamallee , Chennai, Kuthambakkam, Tamil Nadu 602105 ,India . Chennai TAMIL NADU Chennai TAMIL NADU |
9345153967
farida.7fahhima@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| SMCH-IEC |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: B968||Other specified bacterial agents as the cause of diseases classified elsewhere, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Diagnostic kit "Leptoplex" |
Clinical Evaluation of a Novel Multiplex PCR Panel (LipL21, LipL32, LipL41) for Leptospirosis Diagnosis in Kancheepuram District-[LEPTOPLEX] for duration of one year |
| Comparator Agent |
NIL |
NIL |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
65.00 Year(s) |
| Gender |
Both |
| Details |
Patients of all ages and genders presenting with clinical suspicion of leptospirosis and who can provide informed consent written consent for adults greater or equal to 18 years, and parental or guardian consent for minors. |
|
| ExclusionCriteria |
| Details |
Non-suspected cases and patients unable to provide informed consent. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To assess the sensitivity and specificity of the LEPTOPLEX Multiplex PCR assay for diagnosis of leptospirosis. |
Primary outcome (sensitivity and specificity of LEPTOPLEX Multiplex PCR) was assessed at baseline (Day 0), at the time of first clinical presentation, in patients presenting within less than or equal to 7 days of fever onset |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Secondary outcomes included phase-wise diagnostic performance, agreement with MAT, comparison with conventional PCR, turnaround time, gene-wise positivity, and incremental diagnostic yield of the LEPTOPLEX assay. |
Secondary outcomes were assessed at baseline (Day 0), during early (Days 1–3) and late acute phases (Days 4–7), and during the convalescent phase (Days 8–14), with final outcome assessment at Day 14–21 or discharge. |
|
|
Target Sample Size
|
Total Sample Size="30" Sample Size from India="30"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
17/01/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Leptospirosis is an important re emerging zoonotic disease causing acute febrile illness in tropical regions including Tamil Nadu. Early diagnosis is challenging due to non specific clinical presentation and limited sensitivity of serological tests in the initial phase of illness. Microscopic agglutination test though considered the reference standard requires paired sera and is not useful for early clinical decision making. Polymerase chain reaction based methods can detect leptospiremia in the early acute phase and enable timely treatment.
This study aims to clinically evaluate a novel multiplex PCR panel named LEPTOPLEX targeting LipL21 LipL32 and LipL41 genes for the diagnosis of leptospirosis among clinically suspected adult patients in Kancheepuram district. Adult patients aged 18 to 65 years presenting with acute febrile illness suspected to be leptospirosis will be enrolled. Blood samples will be collected at baseline for LEPTOPLEX testing and compared with conventional PCR and serological testing. Convalescent samples will be collected for serological confirmation.
The primary outcome of the study is to assess the sensitivity and specificity of the LEPTOPLEX multiplex PCR assay at baseline during the acute phase of illness. Secondary outcomes include comparison of detection rates with conventional diagnostic methods assessment of turnaround time agreement with serological reference standard and gene wise positivity pattern.
The study is expected to generate evidence on the utility of LEPTOPLEX as a rapid and reliable diagnostic tool for early detection of leptospirosis and to support its potential use in endemic settings for improved case management and disease control |